CX804 / Helixmith - LARVOL DELTA

Development of a novel L1CAM-targeted CAR-T, CX804, and its therapeutic efficacy in ovarian and gastric cancer (AACR 2023) - "Taken together, our results suggest that CX804 exerts potent and specific effect against L1CAM positive cancer cells in vitro and in vivo. Furthermore, we propose that newly established CAR-T cells targeting L1CAM facilitate therapy against L1CAM-positive ovarian and gastric cancer patients"

Clinical • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor • ICOS • IFNG • L1CAM • TNFA

Helixsmith "The speed of development of the follow-up pipeline of Engensys… Preparation for clinical trials such as CAR-T treatment" [Google translation] (Newspim) - "The subsidiary, Catexel, owns CX803, CX804, and CX805, which are chimeric antigen receptor (CAR-T) gene cell therapies. Catexel is a subsidiary of Helixsmith...Catexel will start the phase 1 clinical trial of CX804 for the treatment of neuroblastoma and ovarian cancer in 2023. Next year, it plans to apply for clinical plan approval (IND). Phase 1 clinical trials of CX803 for pancreatic cancer are also being prepared with the goal of starting in 2024."

IND • New P1 trial • Gastrointestinal Cancer • Gynecologic Cancers • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer

How far has local CAR-T therapy development come? (Korea Biomedical Review) - "Helixmith set up a subsidiary, Cartexell, to develop CAR-T therapy in solid cancer. Cartexell is developing CX804 to treat neurocytoma and ovarian cancer. The company is running a pre-clinical trial. 'We plan to start a clinical trial of CX804 in the first half of 2022...'"

New trial • Gynecologic Cancers • Oncology • Ovarian Cancer